TRENDS IN PRIVATE COMPANY FINANCING & EXITS IN OPHTHALMOLOGY
Transcript of TRENDS IN PRIVATE COMPANY FINANCING & EXITS IN OPHTHALMOLOGY
Healthcare Investments and ExitsMid-Year 2016 Report – OIS August 8, 2016
Prepared by:
Jonathan NorrisManaging DirectorSilicon Valley Bank
Healthcare Investments and Exits, Mid-Year 2016 Report
2
Venture Healthcare Topics:
Key Highlights 1H 2016
Healthcare Investments and Fundraising
Healthcare Big Exit M&A and IPO
Cover Photo: Cytotoxic T lymphocytes attacking cancer cell
Healthcare Investments and Exits, Mid-Year 2016 Report
3
Key Highlights 1H 2016: New Patterns Emerge as Investor Confidence Drives DealsLike investing and exits overall, healthcare experienced a bumpy start in 2016 — but also had some surprising highlights.• Venture fundraising declines, but Series A investment is up in all
sectors.• We expect healthcare investment to reach $9B-$9.5B for full-year
2016, down slightly from 2015.
• Crossover investment slows, but newly raised funds, corporate venture and family offices are largely filling the gap. Crossover investors are instead focusing on getting biopharma portfolio companies to an IPO.
• Biopharma round sizes are skyrocketing, while exits focus on early-stage companies.
• Device remains healthy, as M&A big exits are on pace to meet full-year 2015.
• Diagnostics (dx) has experienced exit pullback due to regulatory and reimbursement uncertainty. However, investment has picked up and M&A activity should increase.
4Healthcare Investments and Exits,
Mid-Year 2016 Report
Healthcare Investments and Fundraising: Series A Activity Booms
Healthcare Investments and Exits, Mid-Year 2016 Report
5
With very healthy funding over the last few years, we continue to see strong investment into companies and expect it to continue for at least the next two years.
Based on Q1 2016 data, we think investment into companies will reach $9-$9.5B for the full year, down slightly from 2015. This reflects less crossover activity.
Fundraising in 1H 2016 is down compared to 1H 2015, driven primarily by the closing of three big funds ($2.75B total) in 2015. But we continue to see LP interest in investing into healthcare.
Investors See Strong Future in HealthcareU.S. Healthcare: Capital Invested and VC Dollars Raised
Capital Flow Ratio 127% 368% 207% 189% 175% 149% 141%
HC $ Invested into Companies HC VC $ Fundraised Gap in Funding
2009 2010 2011 2012 2013 2014 20150123456789
1011
$ Bi
llion
s
Source: PricewaterhouseCoopers, Thomson Reuters and SVB proprietary data
$7.5B
$10.5B
Healthcare Investments and Exits, Mid-Year 2016 Report
6
Series A Activity Is Strong across All Sectors
Total Series A ($M) $1,107 $862 $1,843 $994CVC Deals % / # 28% / 17 27% / 20 26% / 23 33% / 19
BIOPHARMA
Biopharma is on pace in 2016 for 100+ Series A deals (up 30% over 2015) with $2B in invested capital. Both would be record highs, if investment velocity continues.
• Significant pre-clinical focus, especially in platform, oncology, anti-infective, neurology and orphan/rare disease companies
Device deals already have eclipsed 2015 totals, driven by angel activity.
• Significant investment activity in neurology, cardiovascular and surgical companies
Dx/tools deals and dollars in 1H 2016 have exceeded 2015 totals, despite an M&A pullback.
• Grail raised $125M in Series A, accounting for almost half of dollars raised in 1H 2016
DEVICE
DX/TOOLS
Total Series A ($M) $227 $337 $92 $104CVC Deals % / # 18% / 7 14% / 6 22% / 4 4% / 1
Total Series A ($M) $234 $252 $165 $263CVC Deals % / # 10% / 4 12% / 4 24% / 4 21% / 5
2013 2014 2015 2016
04080
120
60 75 8758
# o
f Dea
ls
0
40
80
120
38 4218 24
# o
f Dea
ls
0
40
80
120
39 3417 24
# o
f Dea
ls
Source: CB Insights, PitchBook, press releases and SVB proprietary data
U.S. Company Formation: Deals and Investments in Series A
7
Venture and Corporate Investors Keep Active
Healthcare Investments and Exits, Mid-Year 2016 Report
Trends suggest the number of deals by the most active investors will increase 30% over 2015.
Pfizer, a corporate investor, leads all investors with 9 new deals in 1H 2016.
The majority of the most active VCs in 1H 2016 have raised new funds between January 2015 and June 2016.
Active crossover investors include Deerfield Management (7), Fidelity Investors (4) and Cormorant Asset Management (4). See page 13.
Top 2015 VC+CVC BiopharmaINVESTOR DEALS TYPE
OrbiMed Advisors 16 VC
New Enterprise Associates 9 VC
Novartis Venture Funds 9 Corporate
ARCH Venture Partners 8 VC
Sofinnova Ventures 8 VC
Novo 7 VC
Pfizer Venture Investments 7 Corporate
Versant Ventures 7 VC
Celgene 6 Corporate
Johnson & Johnson Innovation 6 Corporate
SR One 6 Corporate
Top 1H 2016 VC+CVC Biopharma
INVESTOR DEALS TYPEPfizer Venture Investments 9 Corporate
OrbiMed Advisors 8 VC
Frazier Healthcare 6 VC
Novo 6 VC
AbbVie Biotech Ventures 5 Corporate
ARCH Venture Partners 5 VC
New Enterprise Associates 5 VC
Canaan Partners 4 VC
MPM Capital 4 VC
Johnson & Johnson Innovation 3 Corporate
Roche Venture Fund 3 Corporate
Most Active* New Investors in Biopharma 2015 versus 1H 2016
*Most active is defined as top 60 investors based on new investments.Source: CB Insights, PitchBook, press releases and SVB proprietary data
8
Oncology Leads New Biopharma Investments
Healthcare Investments and Exits, Mid-Year 2016 Report
Oncology has almost three times the number of deals compared to any other category.
Anti-infective, ranked ninth in number of deals in our 2014 analysis, is now tied for second.
Platform, orphan/rare disease and neurology continue to receive significant investment.
Oncology62 deals$2,419M
Anti-Infective22 deals$686M
Platform22 deals$914M
Neurology22 deals$816M
Orphan/Rare Disease19 deals$749M
Auto-Immune
6 deals$232M
Metabolic9 deals$243M
Cardiovascular
5 deals$109M
Gastrointestinal
6 deals$128M
Respiratory4 deals$155M
Ophthalmology
5 deals$201M
Most Active* New VC Investments in Biopharma by Indication 2015–1H 2016
*Most active is defined as top 60 investors based on new investments.Source: CB Insights, PitchBook, press releases and SVB proprietary data
Healthcare Investments and Exits, Mid-Year 2016 Report
9
Biopharma Deal Size Increases
Median investment round size from most active investors has increased 40% over 2015.
The median deal size has almost tripled since 2013.
Recent larger equity raises in biopharma could compress M&A multiples down the road, especially as IPO optionality declines.
2013 2014 2015 2016$0
$5
$10
$15
$20
$25
$30
$35
$40
$45
$15.3
$23.0
$30.0
$42.8
Med
ian
Dea
l Siz
e ($
Mill
ions
)
Source: CB Insights, PitchBook, press releases and SVB proprietary data
Median Deal Size by Top 60 VC and Corporate Investors
Healthcare Investments and Exits, Mid-Year 2016 Report
10
Device Gains Traction in Large Late-Stage Deals
Active* InvestorsINVESTOR TYPE INVESTOR TYPE
Action Potential Venture Capital Corporate Lightstone Ventures VC
Aisling Capital VC Longitude Capital VC
BioStar Ventures VC Medtronic Corporate
Deerfield Management Crossover New Enterprise Associates VC
Edwards Lifesciences Corporate OrbiMed Advisors VC
Endeavour Vision VC Sante Ventures VC
GE Ventures Corporate Sofinnova Partners VC
HealthQuest Capital VC SV Life Sciences Advisers VC
Johnson & Johnson Innovation Corporate Venrock VC
KCK Group Family Office Vertex Healthcare VC
Analysis of the top 10 1H 2016 device deals:• The median deal size
jumped to $46M in Q2 2016 — the largest median round size in two years.
• The increased deal sizes underscore the funding of late-stage pivotal trial and/or commercialization rounds.
• Cardiovascular received the most investments in 1H 2016; this indication requires significant clinical trial investment. We also saw recent big exit M&A activity in this indication, with 8 of 17 device big exits in 2015.
Active* Investors in Device 1H 2016
*Active defined as investors that are actively investing or actively looking at deals.Source: CB Insights, PitchBook, press releases and SVB proprietary data
11Healthcare Investments and Exits,
Mid-Year 2016 Report
Healthcare Big Exit M&A and IPO:Robust M&A Activity Continues as IPOs Slow
Healthcare Investments and Exits, Mid-Year 2016 Report
12
Strong Biopharma Big Exit M&A Continues, while IPO Market Slows
Q1 Q2 Q3 Q4 Total
2013 IPO 3 10 13 8 34
M&A 3 3 3 3 12
2014IPO 24 12 17 13 66
M&A 3 4 6 1 14
2015IPO 11 12 9 10 42
M&A 7 4 6 4 21
2016IPO 7 8 15
M&A 5 4 9
Source: CB Insights, PitchBook, press releases and SVB proprietary data
VC-backed Biopharma Exits by Quarter 2013–1H 2016 Full-year 2016 biopharma IPOs are estimated to come close to the 2013 total.
Of the 15 IPOs in 1H 2016, 7 companies were trading above their IPO price and 8 trading below at the end of the first half of 2016.
We anticipate M&A big exits to pick up in 2H 2016 and exceed the 2015 total.
13
Early-Stage Companies Dominate Biopharma IPOs
Healthcare Investments and Exits, Mid-Year 2016 Report
Stage 2012 2013 2014 2015 1H 2016
Pre-Clinical / Phase I 1 9 29 18 9
Total Biopharma IPOs 10 34 66 41 15
% Early-Stage IPOs 10% 26% 44% 44% 60%
Biopharma IPOs were focused predominantly on early-stage companies in 1H 2016.
In 1H 2016, median IPO dollars raised was $53M, down from $75M in 2H 2015. Median pre-money valuation in 1H 2016 of $176M is healthy, but below the 2H 2015 median of $233M.
Following a strong 2015 for neurology and anti-infective IPOs, these indications had none in 1H 2016. This may be related to recent clinical setbacks at newly public companies.
Source: CB Insights, PitchBook, press releases and SVB proprietary data
VC-backed Biopharma IPOs by Stage 2012–1H 2016
14
Biopharma M&A Big Exit Multiples Surge;Early-Stage Focus Continues
Healthcare Investments and Exits, Mid-Year 2016 Report
Pre-Clinical Phase I Phase II Phase III Commercial
2012 2013 2014 2015 20160
2
4
6
8
10
12
14
16
18
20
# o
f Big
Exi
ts
Source: CB Insights, PitchBook, press releases and SVB proprietary data
VC-backed Biopharma Big Exit M&A by Stage 2012–1H 2016Biopharma deals in 1H 2016 had a strong median upfront multiple of 4.7X. Even more impressive, the median all-in multiple reached 14X, up significantly from 2014 and 2015.
7 of 9 M&A big exits were pre-clinical or Phase I:
• Pre-clinical deals were in neurology, auto-immune and orphan/rare disease.
• Phase I deals were in oncology (2 deals), metabolic and aesthetics/dermatology.
Healthcare Investments and Exits, Mid-Year 2016 Report
15
Early-Stage Biopharma M&A Remains Strong, while Exit Time Decreases
Source: CB Insights, PitchBook, press releases and SVB proprietary data
2012 2013 2014 2015 1H 2016$0.0
$100.0$200.0$300.0$400.0$500.0$600.0$700.0
0.01.02.03.04.05.06.0
$325M
$500M$413M
$600M$600M
5.04.1
5.3 5.6 4.7
Median Total Deal Size and Time to Exit (Pre-Clinical & Phase I)
Median Total Deal Size Median Time to Exit (years)
n=5 n=3 n=8 n=11 n=7
2012 2013 2014 2015 1H 2016
31.8%51.7%
74.0%
36.9% 51.2%
68.2%48.3%
26.0%
63.1% 48.8%
Median Total Deal Size (Pre-Clinical & Phase I)
Upfront % Milestone %
$325M $500M $413M $600M $600M
M&A median total deal size remains at record high, even as IPO optionality is decreasing.
This suggests competition among acquirers, which is leading them to pay more at deal close to acquire early-stage assets.
Biopharma M&A continues to show a quick time to exit.
Healthcare Investments and Exits, Mid-Year 2016 Report
16
Device Big Exit M&A Charges On as IPOs Disappear
Q1 Q2 Q3 Q4 Total
2013 IPO 0 0 0 2 2
M&A 2 2 6 2 12
2014IPO 1 5 1 3 10
M&A 2 9 5 2 18
2015IPO 3 4 3 1 11
M&A 0 4 9 4 17
2016IPO 0 0 0
M&A 5 4 9
Source: CB Insights, PitchBook, press releases and SVB proprietary data
VC-backed Device Exits by Quarter 2013–1H 2016In 1H 2016 there were no device IPOs, but we did see some reverse merger activity.
At the same time, there were 9 M&A big exits — on pace to match the 2015 total.
In each of the past five quarters, there have been at least four M&A device big exits.
Healthcare Investments and Exits, Mid-Year 2016 Report
17
Device Big Exit M&A Trends to Later Stage
Non-Approved CE Mark U.S. CommercialRepresents # of IPOs Represents Big Exits
2012 2013 2014 2015 20160
2
4
6
8
10
12
14
16
18
# o
f Big
Exi
ts
1 2
7
1
2
8
1
2
Source: CB Insights, PitchBook, press releases and SVB proprietary data
The orthopedic indication leads with three deals in 1H 2016.
There were no Medtronic venture-backed acquisitions in 1H 2016 (13 big exit acquisitions in 2014-2015). However, we expect Medtronic activity in 2H 2016.
Discussions with investors suggest that the next flurry of early stage acquisitions could focus on atrial fibrillation, heart failure, stroke or neurostimulation.
VC-backed Device Big Exit M&A by Stage 2012–1H 2016
Healthcare Investments and Exits, Mid-Year 2016 Report
18
Device Big Exit M&A Propels Higher Median Values
MedianUpfront ($M) $95 $127 $180 $150 $120
MedianTotal Deal
($M)$195 $175 $185 $219 $300
MedianYears to Exit 7.0 6.6 6.9 5.5 9.2
# of Structured Deals # of All-In Deals
2012 2013 2014 2015 201602468
101214161820
# o
f Big
Exi
ts
Source: CB Insights, PitchBook, press releases and SVB proprietary data
In 1H 2016, 7 of 9 M&A device big exits were structured. There have never been more than 50% structured deals in any year.
Looking at regulatory pathways in 1H 2016, the majority of deals (6 of 9) are 510k pathway. These companies typically require revenue ramp-up prior to acquisition. This helps to explain the longer time to exit and later-stage focus.
VC-backed Device Big Exit M&A Deal Structure 2012–1H 2016
Healthcare Investments and Exits, Mid-Year 2016 Report
19
Ophthalmology #4 Indication in Device and Biopharma Exits since 2013
Source: CB Insights, PitchBook, press releases and SVB proprietary data
In venture-backed Big Exit M&A and IPOs Ophthalmology is in the top 5 and top 6 in IPOs and M&A
In overall exits (M&A + IPO), Ophthalmology ties for #4
VC-backed Big Exit M&A and IPO by Indication 2013 – 1H 2016IPO Big Exit M&AOncology 36Cardiovascular 18Neurology 23 Oncology
15Orphan/Rare 15 Neurology 12Anti-Infective 12 Vascular
10Ophthalmology 11 Surgical
10Ophthalmology 8
Healthcare Investments and Exits, Mid-Year 2016 Report
20
Glossary
Big ExitBig Exits are defined as private, venture-backed merger and acquisition transactions in which the upfront payment is $75 million or more for biopharma deals and $50 million or more for device and dx/tools deals.
Initial Public OfferingIPO is defined as a venture-backed company raising IPO proceeds more than $25 million.
Deal DescriptionsStructured DealThis is a pay-for-performance system that pays some of the consideration upfront, but sets milestones in development that must be achieved before the full value of the transaction will be realized.All-in DealAll consideration for the deal is paid when the deal closes.Big Exit Upfront PaymentsThe upfront payment refers to payments in a structured deal that are made at the close of the deal; it does not include milestones.Big Exit Milestones to be EarnedThe milestones to be earned refer to payments in a structured deal that are made after the pre-determined goals are met.Total Deal ValueThe total deal value of a structured deal includes both the upfront payment and the milestones to be earned.
Regulatory DefinitionsNon-approvedNon-approved refers to a device company that has no regulatory approval for its product.CE MarkCE Mark refers to a device company that has a CE Mark-only product. CE Mark is a European Union designation that is less difficult to obtain than FDA approval, and the approval process typically has a faster timeline.U.S. CommercialCommercial refers to a device company that has an FDA-approved product, and typically is in commercial stage. Series ASeries A companies are defined as U.S. companies raising their first round greater than $2 million in equity or backed by institutional or corporate venture capital.
Indication DefinitionNeurologyCNS, pain, and psychology comprise neurology.
Healthcare Investments and Exits, Mid-Year 2016 Report
21
About the Author
Jonathan NorrisJonathan Norris is a managing director for SVB's Life Science and Healthcare practice. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on limited partnership allocations.
In addition, he speaks at major investor and industry conferences and authors widely cited analyses of healthcare venture capital trends. Norris has more than sixteen years of banking experience working with healthcare companies and venture capital firms. Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.
Managing DirectorSilicon Valley [email protected]
Healthcare Investments and Exits, Mid-Year 2016 Report
22
About Silicon Valley BankFor more than 30 years, Silicon Valley Bank has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international and private banking services, SVB helps address the unique needs of innovators.
This material, including without limitation to the statistical information herein, is provided for informational purposes only. The material is based in part on information from third-party sources that we believe to be reliable, but which have not been independently verified by us and for this reason we do not represent that the information is accurate or complete. The information should not be viewed as tax, investment, legal or other advice nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision. Nothing relating to the material should be construed as a solicitation, offer or recommendation to acquire or dispose of any investment or to engage in any other transaction. ©2016 SVB Financial Group. All rights reserved. Silicon Valley Bank is a member of FDIC and Federal Reserve System. SVB>, SVB Financial Group, and Silicon Valley Bank are registered trademarks. 0716-160
Insert image Send to Back
Healthcare Investments and Exits, Mid-Year 2016 Report
23